A Collection of Articles
Edit

Biomedicine

Low Road to Market

Highly touted “gene chips” are entering clinical use but not as biological crystal balls. Their more mundane role: assessing the stage of a tumor.

Science writers have expended a great many words on “gene chips,” which are being touted as biological crystal balls that will diagnose future genetic susceptibility to disease. Having contributed my share of adjectives to this futuristic vision, I know how tempting it is to describe.

But technologies often travel the low road to widespread use, and while prognostic gene chips may well be a routine feature of annual physical checkups in the future, a related chip application has already entered the clinic through the back door. “Molecular profiling” is one name this technology goes by, and these highly precise genetic tests do not exactly predict the future. Rather, these chips assess the molecular stage of a patient’s disease, and may ultimately suggest which drugs the patient might respond to.

It takes a genetic disease to beget a genetic test, and one of the most inviting targets-for marketing as well as molecular reasons-is a tumor-suppressor gene known as p53. Even in this frenzied “Gene-of-the-Week” era of biological discovery, p53 is a legitimate cover boy for the genetics of cancer, having earned the appellation of “Molecule of the Year” from the journal Science in 1993 and later appearing on the cover of Newsweek.

The reason for this celebrity is that the p53 gene, in its normal and intact state, plays the bouncer inside the velvet rope of a cell, mindful of the slightest aberrant behavior, such as the unchecked replication typical of cancer cells. The gene essentially orders a disobedient cell to commit suicide, which is an excellent biological way to suppress the rise of incipient tumors. Tumor cells grow better when p53 is inactivated by mutations, so there is strong Darwinian selection for cancer cells that shut off p53. Indeed, fully 50 percent of all human cancers are marked by disabled p53 function, including major killers like lung, breast, and colon.

Given its importance, clinicians would like to know the p53 status of every tumor they’re trying to treat. About two years ago, biochip-maker Affymetrix joined forces with Oncormed, a cancer diagnostics company based in Gaithersburg, Md., to make p53 testing one of the prototypes of chip technology. Their target: the coding region of the human p53 gene, which possesses 1,262 base pairs of DNA-the chemical subunits of the double helix that tell a cell how to make the p53 protein.

Affymetrix, based in Santa Clara, Calif., has created a p53 chip that measures slightly less than 13 millimeters square-bigger than a thumbtack, but smaller than the standard issue 32-cent stamp. Engineers at Affymetrix have subdivided this real estate into a checkerboard of 20,000 “probe cells,” each bristling with a uniform carpet of millions of identical DNA probes measuring 18 base pairs long. Using fluorescently labeled reagents, prepared DNA from a tumor can be washed over the chip, and extremely sensitive scanners are programmed to detect minuscule variations in intensity in the checkerboard pattern-which arise from slight genetic changes in p53. Once the DNA has been prepared, the test can be done in four hours.

Although p53 is only one of numerous genes implicated in the evolution of a tumor, it has already been thrust into a prominent role in experimental cancer treatments. In April of 1996, for example, Oncormed began using the Affymetrix chip to perform “molecular staging”-that is, assessing the status of a tumor-in patients with head and neck cancers prior to clinical testing of an experimental form of gene therapy developed by Onyx Pharmaceuticals. The therapy is in Phase II testing, and some patients have responded favorably in preliminary results.

The ability to do molecular profiling, according to Leslie Alexandre, a vice president at Oncormed, allows oncologists to determine both the virulence of a tumor and the extent of its metastatic spread. “If there is a p53 mutation in the tumor,” she says, “then you would look at the lymph nodes and look for the fingerprint to see how far the tumor has spread.” Oncormed has reached agreements with Rhone-Poulenc Rorer and Schering-Plough to do p53 testing associated with gene therapy trials.

The potential significance of such testing goes well beyond staging individual tumors. Drug companies are intensely interested in ways of predicting which patients are likely to respond to chemotherapy, and there is some evidence that p53-and molecular profiling like it-may help identify patients likelier to respond. Not only will this allow drug companies to achieve higher response rates in drugs being tested, but it may, Alexandre says, provide a way to “resurrect” drugs that fail in Phase III trials by identifying a small group for whom the drug is very effective.

As with many new technologies, there may be a social cost to molecular profiling. The most precious resource available to any cancer patient is not money, but hope. Tests based on the p53 chip and related chips may turn out to be one more sophisticated, definitive, and molecular way of telling a patient there is no hope.

Uh oh–you've read all five of your free articles for this month.

Insider basic

$29.95/yr US PRICE

Subscribe
What's Included
  • 1 year (6 issues) of MIT Technology Review magazine in print OR digital format
  • Access to the entire online story archive: 1997-present
  • Special discounts to select partners
  • Discounts to our events

You've read of free articles this month.